Aim Antimuscarinics and the β3‐adrenoreceptor agonist, mirabegron, are commonly used
for treating patients with overactive bladder (OAB) and α1‐adrenoreceptor antagonists (α1 …

Reviews assessing mirabegron's safety and efficacy, synthesize data from both genders,
without providing specific details for female patients with OAB. The aim of this study is to …

Background Current research is starting to focus on the medical value of marijuana and the
possible health problems it can cause. Previous studies have shown that marijuana can …

The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic
function and peripheral arterial conditions in women with overactive bladder syndrome …

To observe the efficacy and safety of solifenacin and/or mirabegron as a medical expulsive
therapy (MET) in patients with double-J stent-related overactive bladder (OAB) symptoms. A …

Background: Vibegron is a new β3-adrenergic receptor agonist which has been
demonstrated for the treatment of overactive bladder (OAB). We carried out meta-analysis to …

Lower urinary tract symptoms (LUTS), including urgency, frequency, and urgency
incontinence, are highly prevalent in the general population and increase in prevalence with …

Object: The aim of this study was to prepare injectable, adhesive, and self-healing
composite hydrogels loaded with oxybutynin hydrochloride and verify its function in the …

Objectives: To compare the therapeutic efficacy, adverse events (AEs), and patient
preference in elderly patients with overactive bladder (OAB) receiving different combinations …

Aim We investigated the satisfaction and efficacy of mirabegron in patients with overactive
bladder (OAB) symptoms who were unsatisfied with previous antimuscarinic treatment …